Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Molecular Glue ERAS-0015 Shows Early Tumour Shrinkage in Phase I Cancer Trial

10 hours ago 8

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

Preliminary findings from the ongoing AURORAS-1 phase I clinical trial demonstrate that an investigational anti-cancer agent designated ERAS-0015 has shown manageable safety and caused measurable tumour shrinkage in individuals diagnosed with difficult-to-treat malignancies, specifically advanced non-small cell lung cancer and pancreatic cancer. These early human clinical results were formally presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics conducted in Barcelona, Spain. The findings derive from an analysis involving 148 evaluated clinical trial participants harboring genetic alterations in the RAS family of oncogenes.

Historically, malignant tumours whose progression and uncontrolled cellular division are propelled by mutations within the RAS gene family have represented an immense challenge in therapeutic drug development. The therapeutic approach under investigation with ERAS-0015 represents an emerging mechanistic strategy designed specifically to address this long-standing clinical hurdle by targeting tumours directly driven by these diverse genetic anomalies across multiple cancer presentations.

At the biochemical level, ERAS-0015 operates as a targeted pan-RAS molecular glue. Under normal physiological circumstances, molecular switches regulate cellular signaling cascades, but specific oncogenic RAS mutations function much like a signaling switch that is persistently locked into an active on position. This dysregulated activation continuously conveys biochemical signals downstream that initiate and sustain malignant growth. The molecular glue mechanism of ERAS-0015 physically brings distinct proteins together at the sub-cellular molecular level. By binding directly to the RAS switch conformation while it remains in this active on state, the agent successfully blocks the ongoing downstream growth signals across several distinct cancer-driving RAS alterations.

As articulated by medical oncologist Dr Judy Wang of the Florida Cancer Specialists and Research Institute, precision oncology seeks to pinpoint an individual patient’s underlying oncogenic driver—frequently characterized as the Achilles heel of that specific tumor—and align it with a pharmaceutical compound engineered to disrupt that precise vulnerability. The AURORAS-1 clinical investigation is structured specifically to evaluate whether the application of ERAS-0015 can realize this precision medicine paradigm in human patients whose malignancies harbor defined RAS alterations, particularly among individuals who have exhausted conventional frontline cancer regimens.

Initiated in June 2025, the AURORAS-1 trial is designed to investigate the pharmacological profile, safety, and therapeutic activity of ERAS-0015 administered as a single-agent monotherapy as well as in combination with other anti-cancer treatments. The trial population comprises individuals living with various forms of RAS-mutant solid tumours. Specifically, the study cohort includes patients diagnosed with locally advanced or metastatic non-small cell lung cancer that has progressed beyond the primary anatomic site, alongside individuals presenting with advanced pancreatic cancer, colorectal bowel cancer, and other relevant solid tumour classifications.

The preliminary clinical data presented in Barcelona focused on defined subgroups within the trial, comprising 83 patients with pancreatic cancer and 37 patients with non-small cell lung cancer. Over an average median follow-up duration spanning just over four months, investigators observed that the formal maximum tolerated dose of the investigational drug had not been reached, with the overall clinical protocol continuing its patient enrollment activities.

Within the cohort treated at the specific dose level of 32 mg of ERAS-0015, investigators documented measurable antitumour responses among heavily pre-treated participants. Among 25 evaluable patients with pancreatic cancer who received the 32 mg dosage and had previously undergone standard cytotoxic chemotherapy, tumours shrank in eleven patients, establishing an objective response rate of 44 percent. In the lung cancer cohort, five evaluable participants who had experienced disease progression following prior platinum-based chemotherapy or immune checkpoint inhibitor therapy received the 32 mg dose, with three of those five individuals experiencing notable tumour regression, corresponding to a 60 percent response rate.

Assessment of the compound’s safety profile indicated that ERAS-0015 was generally well tolerated among the treated trial population. Across the wider evaluated safety group, twelve patients, representing 9.8 percent of participants, reported severe treatment-related side effects classified as grade 3 or higher.

Despite these encouraging early biological responses, investigators emphasize that the findings remain subject to the inherent limitations of phase I first-in-human clinical evaluations, which inherently study relatively small and constrained cohorts of selected patients over preliminary observation windows. Dr Wang and independent specialists note that subsequent exploration in substantially larger patient cohorts across planned phase II and phase III clinical trials will be essential to definitively establish the reproducibility, long-term safety, and ultimate efficacy profile of ERAS-0015 in broader clinical environments.

Commenting as an independent observer, Professor Elena Garralda, chair of the EORTC-NCI-AACR Symposium and co-director of the Vall d’Hebron Institute of Oncology’s clinical research programme, emphasized that these preliminary results provide initial proof-of-concept for the pan-RAS inhibitor class in cancers notoriously lacking effective secondary options. As part of a broader shift in clinical cancer research demonstrating that previously intractable RAS mutations can indeed be modulated by newly developed molecular glue compounds, the continued clinical progression of AURORAS-1 will determine whether ERAS-0015 can ultimately be validated as a broader treatment avenue for patients facing advanced solid tumours.

In her address to the symposium, Dr. Judy Wang, a medical oncologist at Florida Cancer Specialists and Research Institute in Sarasota, United States, detailed the clinical relevance of the trial outcomes for heavily pretreated individuals. Dr. Wang explained that a response within the AURORAS-1 study indicates that patients experienced considerable tumour shrinkage. Achieving such reductions is clinically meaningful because the enrolled participants had already tried multiple cancer treatments and faced few, if any, remaining therapeutic choices. Demonstrating a 44 percent response rate in RAS-mutant pancreatic cancer alongside a 60 percent response rate in RAS-mutant lung cancer suggests that ERAS-0015 can deliver tangible antitumour activity while maintaining an acceptable safety profile characterized by few severe adverse effects.

The findings presented in Barcelona formed part of Abstract number 8, titled “Preliminary safety, pharmacokinetics, and efficacy of ERAS-0015: Results from the AURORAS-1 first-in-human trial.” Delivered by Dr. Wang during the proffered papers plenary session on Friday, 20 November, the report contributed to the broader scientific programme of the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, held from 18 to 20 November 2026.

Emphasizing the ultimate translational aims of the research program, Dr. Wang noted that the overarching goal is to equip clinicians with newer and better therapeutic options for treating individuals diagnosed with RAS-driven malignancies. If verified across subsequent phase II and phase III clinical studies with larger patient enrollments, ERAS-0015 could deliver a new option for individuals with hard-to-treat diseases. Dr. Wang concluded by expressing gratitude to the patients, caregivers, investigators, and participating trial centres whose partnership and trust remain indispensable to the clinical development of the drug.

Subject of Research: Preliminary safety and clinical activity of ERAS-0015 in RAS-mutant solid tumours

Article Title: ‘Pan-RAS molecular glue’ is a safe and effective treatment for lung and pancreatic cancers

Article References: ‘Pan-RAS molecular glue’ is a safe and effective treatment for lung and pancreatic cancers. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: ERAS-0015, AURORAS-1, pan-RAS molecular glue, phase I clinical trial, pancreatic cancer, non-small cell lung cancer, RAS mutations, precision oncology, Dr Judy Wang, EORTC-NCI-AACR Symposium, solid tumours, maximum tolerated dose, tumour shrinkage, clinical oncology, cancer therapeutics, molecular targets

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway